l-selectin

Bimosiamose disodium has anti-inflammatory effects[1]. Bimosiamose disodium (TBC-1269Z) is a nonoligosaccharide pan-selectin inhibitor with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively.

Bimosiamose has anti-inflammatory effects[1]. Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, L-selectin, and P-selectin respectively.

Sialyl-Lewis X (sLeX), a sialylated fucosylated tetrasaccharide and endogenous antigen, serves as a high-affinity ligand for selectins (E-, P-, and L-selectin)[1]. It interacts with ELAM-1 and CD62, consequently inhibiting CD62-mediated neutrophil recruitment to inflammation sites[2].

Aselizumab (HuDreg-55)是一种针对L-选择素(L-selectin)的人源化IgG4单克隆抗体。L-选择素(CD62L)，作为循环中性粒细胞表面的一种细胞黏附分子，负责调控细胞向受损组织的趋化作用。应用Aselizumab可能会导致患者经历高发感染率及白细胞减少的副作用。